Advertisement
Organisation › Details
Anjarium Biosciences AG
Anjarium is focused on creating a new class of non-viral gene therapies to deliver more predictable, enduring, and inclusionary ways to tackle genetic disease throughout a patient’s lifetime. The Company’s versatile platform aims to leverage breakthrough science and expertise at the interface of genetic medicine, synthetic biology and nanoparticle engineering to generate a pipeline of advanced gene therapies with unique competitive advantages over current viral-vector based gene therapies. Investors in Anjarium include leading international and strategic investors Abingworth, Gimv, Omega Funds, Pfizer Ventures and Surveyor Capital (a Citadel company). *
Start | 2021-09-16 existent | |
Industry | gene therapy | |
Industry 2 | Hybridosome™ technology | |
Person | Yoo, Stephen (Anjarium Biosciences 202206– CEO before Third Harmonic Bio + Regenxbio + MedImmune + Abbott Labs) | |
Person 2 | Muralidhar, Bali (Abingworth 202109 Managing Partner before MVM Life Science Partners 201404 Partner) | |
Region | Schlieren ZH | |
Country | Switzerland | |
Street | 25 Wagistr. | |
City | 8952 Schlieren | |
Tel | +41-44-552-3888 | |
Address record changed: 2024-01-05 | ||
Basic data | Employees | A: 1 to 10 (2022-01-01) |
* Document for »About Section«: Anjarium Biosciences AG. (9/16/21). "Press Release: Anjarium Biosciences Raises CHF 55.5M ($61M) Series A Financing to Develop Next-Generation Non-viral Gene Therapies". Schlieren. | ||
Record changed: 2023-07-10 |
Advertisement
More documents for Anjarium Biosciences AG
- [1] Anjarium Biosciences AG. (7/12/22). "Press Release: Anjarium Biosciences Appoints Experienced Industry Executives Samantha Vieira as Chief Operating Officer and Nate Massari as Chief Business Officer". Zurich....
- [2] Anjarium Biosciences AG. (6/14/22). "Press Release: Anjarium Biosciences Appoints Stephen Yoo, MD as Chief Executive Officer". Schlieren....
- [3] Anjarium Biosciences AG. (9/16/21). "Press Release: Anjarium Biosciences Raises CHF 55.5M ($61M) Series A Financing to Develop Next-Generation Non-viral Gene Therapies". Schlieren....
To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«
Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]
Please visit also our web portals for the European life sciences and the worldwide mass spectrometry industry at Life-Sciences-Europe.com (European life sciences) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)
Advertisement
» top